That is the cumulative equity balance on the Balance Sheet. It is true that Elite has operated in the red for far too long and relied on dilution in lieu of positive earnings and cash flow to propel the business forward. Dilution has been a trickle for the past several quarters. This dilutive chapter is quickly coming to an end where both cash flow and earnings will take this company to a new level.
- Methadone profit split will start coming in, which will help as mfg fees must be minimal for this. Revenue basically doubled vs previous quarter, but profitability didn’t move (R&D story).
- Adderall launch with Lannett forthcoming.
- Smaller drugs launched with Glenmark will pay for Friday egg McMuffins
- Isradipine will not have change on rev immediate term that will be noticeable. If results are good on May 7th, label needs to be changed for PD and that could require more studies. But drives up intrinsic value of company priming for a sale.
Lots going on this year, especially over next couple quarters.
News 
Market Data 
Discover 
